The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges

• Published in: Medical Review 2024-06, Vol.4 (3), p.173-191
• Main Authors: Zhou, Zheqi, Huang, Sanling, Fan, Fangying, Xu, Yan, Moore, Casey, Li, Sirui, Han, Chuanhui
• Format: Article
• Language: English
• Subjects: cGAS; IFN-I; Review; STING agonist; tumor
• ISSN: 2749-9642; 2097-0773; 2749-9642
• DOI: 10.1515/mr-2023-0061

As a key sensor of double-stranded DNA (dsDNA), cyclic GMP-AMP synthase (cGAS) detects cytosolic dsDNA and initiates the synthesis of 2′3′ cyclic GMP-AMP (cGAMP) that activates the stimulator of interferon genes (STING). This finally promotes the production of type I interferons (IFN-I) that is crucial for bridging innate and adaptive immunity. Recent evidence show that several antitumor therapies, including radiotherapy (RT), chemotherapy, targeted therapies and immunotherapies, activate the cGAS-STING pathway to provoke the antitumor immunity. In the last decade, the development of STING agonists has been a major focus in both basic research and the pharmaceutical industry. However, up to now, none of STING agonists have been approved for clinical use. Considering the broad expression of STING in whole body and the direct lethal effect of STING agonists on immune cells in the draining lymph node (dLN), research on the optimal way to activate STING in tumor microenvironment (TME) appears to be a promising direction. Moreover, besides enhancing IFN-I signaling, the cGAS-STING pathway also plays roles in senescence, autophagy, apoptosis, mitotic arrest, and DNA repair, contributing to tumor development and metastasis. In this review, we summarize the recent advances on cGAS-STING pathway’s response to antitumor therapies and the strategies involving this pathway for tumor treatment.